MCID: LYD001
MIFTS: 45

Leydig Cell Tumor

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Leydig Cell Tumor

MalaCards integrated aliases for Leydig Cell Tumor:

Name: Leydig Cell Tumor 12 54 44 15 17 70
Leydig Cell Tumor, Benign 70
Leydig Cell Neoplasm 12
Tumor, Leydig Cell 39

Classifications:



External Ids:

Disease Ontology 12 DOID:2696
MeSH 44 D007984
NCIt 50 C3188 C4213
SNOMED-CT 67 45002009 77870005
UMLS 70 C0023601 C0334409 C0334410

Summaries for Leydig Cell Tumor

Disease Ontology : 12 A sex cord-gonadal stromal tumor that secretes testosterone characterized by excessive proliferation of Leydig cells located in ovary or testicle.

MalaCards based summary : Leydig Cell Tumor, also known as leydig cell tumor, benign, is related to testicular leydig cell tumor and sertoli-leydig cell tumor. An important gene associated with Leydig Cell Tumor is LHCGR (Luteinizing Hormone/Choriogonadotropin Receptor), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Glucose / Energy Metabolism. The drugs Bevacizumab and Ipilimumab have been mentioned in the context of this disorder. Affiliated tissues include ovary, testis and pituitary, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Related Diseases for Leydig Cell Tumor

Diseases related to Leydig Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 287)
# Related Disease Score Top Affiliating Genes
1 testicular leydig cell tumor 32.8 INSL3 CYP21A2
2 sertoli-leydig cell tumor 32.3 SYP INSL3 INHA CYP17A1 CALB2 AFP
3 gynecomastia 30.9 PRL INHA GNRH1 CYP21A2 CYP19A1
4 testicular cancer 30.9 LHCGR INSL3 GNRH1 AFP
5 teratoma 30.8 SYP CALB2 AFP
6 estrogen excess 30.7 PRL GNRH1 CYP19A1
7 precocious puberty 30.7 LHCGR GNRH1 GNAS CYP21A2
8 rete testis adenocarcinoma 30.5 CALB2 AFP
9 leiomyoma 30.5 GNRH1 CYP19A1 CYP17A1
10 cystadenofibroma 30.3 INHA CALB2
11 amenorrhea 30.3 PRL NR5A1 LHCGR GNRH1 CYP19A1 CYP17A1
12 adrenal rest tumor 30.3 NR5A1 INSL3 CYP21A2
13 adrenogenital syndrome 30.2 SYP INHA HSD3BP4 CYP21A2
14 appendix adenocarcinoma 30.2 SYP GNAS
15 adenomyosis 30.1 PRL GNRH1 CYP19A1
16 androgen insensitivity syndrome 30.1 NR5A1 NR0B1 INSL3 CYP17A1
17 ovarian sex-cord stromal tumor 30.1 NR5A1 CALB2
18 granulosa cell tumor of the ovary 30.0 SYP PRL INHA
19 hyperandrogenism 30.0 PRL INSL3 GNRH1 CYP21A2 CYP19A1 CYP17A1
20 hypogonadism 30.0 PRL NR0B1 LHCGR GNRH1
21 anovulation 29.9 PRL GNRH1 CYP21A2 CYP19A1
22 adrenal adenoma 29.8 GNAS CYP21A2 CYP17A1 CYP11A1
23 adenoma 29.8 SYP PRL LHCGR GNAS CYP21A2
24 cystadenoma 29.7 SYP INHA GNAS CALB2 AFP
25 sertoli cell tumor 29.6 SYP NR5A1 INHA CYP19A1 CALB2 AFP
26 peutz-jeghers syndrome 29.6 INHA GNAS CYP19A1
27 hyperprolactinemia 29.4 PTHLH PRL GNRH1 GNAS
28 mccune-albright syndrome 29.4 PTHLH PRL GNAS CYP19A1
29 polycystic ovary syndrome 29.3 STAR PRL GNRH1 CYP21A2 CYP19A1 CYP17A1
30 adrenal cortical adenoma 29.3 SYP NR5A1 INHA CYP21A2 CYP17A1 CYP11A1
31 lipoid congenital adrenal hyperplasia 29.2 STAR NR5A1 NR0B1 GNRH1 CYP21A2 CYP19A1
32 male infertility 29.0 PRL NR5A1 LHCGR INSL3 INHA GNRH1
33 hypogonadotropic hypogonadism 29.0 PRL NR5A1 NR0B1 LHCGR INSL3 GNRH1
34 ovarian cyst 29.0 PRL HSD3BP4 GNRH1 GNAS CYP19A1 AFP
35 ovarian disease 29.0 STAR PRL LHCGR GNRH1 CYP19A1 CYP17A1
36 infertility 29.0 PRL NR5A1 LHCGR INSL3 INHA GNRH1
37 conn's syndrome 28.9 PRL LHCGR GNRH1 GNAS CYP21A2 CYP17A1
38 cryptorchidism, unilateral or bilateral 28.3 STAR PRL NR5A1 NR0B1 LHCGR INSL3
39 adrenal cortical carcinoma 27.4 SYP STAR NR5A1 NR0B1 INHA GNAS
40 disorder of sexual development 27.4 STAR PRL NR5A1 NR0B1 LHCGR INSL3
41 malignant sertoli-leydig cell tumor of the ovary 11.5
42 infant gynecomastia 10.8
43 rare tumor 10.6
44 azoospermia 10.5
45 rhabdomyosarcoma 10.4
46 peritoneal benign neoplasm 10.4 GNRH1 CALB2
47 rete testis neoplasm 10.4 CALB2 AFP
48 adult type testicular granulosa cell tumor 10.4 CALB2 AFP
49 dermoid cyst of ovary 10.4 CALB2 AFP
50 epididymal neoplasm 10.4 CALB2 AFP

Graphical network of the top 20 diseases related to Leydig Cell Tumor:



Diseases related to Leydig Cell Tumor

Symptoms & Phenotypes for Leydig Cell Tumor

MGI Mouse Phenotypes related to Leydig Cell Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 AFP CALB2 CYP11A1 CYP17A1 CYP19A1 CYP21A2
2 endocrine/exocrine gland MP:0005379 10.22 AFP CYP11A1 CYP19A1 GNAS GNRH1 INHA
3 homeostasis/metabolism MP:0005376 10.18 AFP CYP11A1 CYP17A1 CYP19A1 GNAS GNRH1
4 liver/biliary system MP:0005370 9.97 AFP CYP11A1 CYP19A1 GNAS GNRH1 INHA
5 normal MP:0002873 9.81 CALB2 CYP11A1 CYP19A1 GNAS GNRH1 INHA
6 neoplasm MP:0002006 9.8 AFP GNAS GNRH1 INHA NR0B1 PRL
7 reproductive system MP:0005389 9.77 AFP CYP11A1 CYP17A1 CYP19A1 GNRH1 INHA
8 skeleton MP:0005390 9.28 CYP11A1 CYP17A1 CYP19A1 GNAS GNRH1 INHA

Drugs & Therapeutics for Leydig Cell Tumor

Drugs for Leydig Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2 216974-75-3
2
Ipilimumab Approved Phase 2 477202-00-9
3
nivolumab Approved Phase 2 946414-94-4
4
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
5
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
6
Etoposide Approved Phase 2 33419-42-0 36462
7
Bleomycin Approved, Investigational Phase 2 11056-06-7 5360373
8
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
9 Angiogenesis Inhibitors Phase 2
10 Immunoglobulin G Phase 2
11 Mitogens Phase 2
12 Immunoglobulins, Intravenous Phase 2
13 Immunologic Factors Phase 2
14 Endothelial Growth Factors Phase 2
15 Antineoplastic Agents, Immunological Phase 2
16 Immunoglobulins Phase 2
17 Antibodies Phase 2
18 Antibodies, Monoclonal Phase 2
19 Tubulin Modulators Phase 2
20 Etoposide phosphate Phase 2
21 Antimitotic Agents Phase 2
22 Albumin-Bound Paclitaxel Phase 2
23 Antibiotics, Antitubercular Phase 2
24 Anti-Bacterial Agents Phase 2
25
Gemcitabine Approved Phase 1 95058-81-4 60750
26 Immunosuppressive Agents Phase 1
27 Anti-Infective Agents Phase 1
28 Antiviral Agents Phase 1
29 Antimetabolites Phase 1
30
Vincristine Approved, Investigational 2068-78-2, 57-22-7 5978
31
Doxorubicin Approved, Investigational 23214-92-8 31703
32
Cyclophosphamide Approved, Investigational 50-18-0, 6055-19-2 2907
33
Dactinomycin Approved, Investigational 50-76-0 2019 457193
34
Ifosfamide Approved 3778-73-2 3690
35
Isophosphamide mustard 100427
36
Liposomal doxorubicin 31703

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Phase II Trial of NCI-Supplied Agent: Bevacizumab (rhuMAB VEGF) (NSC# 704865) for Recurrent Sex Cord-Stromal Tumors of the Ovary Completed NCT00748657 Phase 2
2 Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy Completed NCT00006227 Phase 2 Paclitaxel
3 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Recruiting NCT03866382 Phase 2 Cabozantinib S-malate
4 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary Active, not recruiting NCT01042522 Phase 2 Carboplatin;Cisplatin;Etoposide Phosphate;Paclitaxel
5 A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
6 DICER1 Mutations and miRNA in Ovarian and Testicular Sex Cord Stromal Tumors of Childhood Completed NCT01572467
7 A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence Completed NCT01764789
8 International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions Recruiting NCT03382158
9 DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study Recruiting NCT01247597
10 Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome Active, not recruiting NCT00565903

Search NIH Clinical Center for Leydig Cell Tumor

Cochrane evidence based reviews: leydig cell tumor

Genetic Tests for Leydig Cell Tumor

Anatomical Context for Leydig Cell Tumor

The Foundational Model of Anatomy Ontology organs/tissues related to Leydig Cell Tumor:

19
Ovary

MalaCards organs/tissues related to Leydig Cell Tumor:

40
Ovary, Testis, Pituitary, Thyroid, Testes, Cervix, Endothelial

Publications for Leydig Cell Tumor

Articles related to Leydig Cell Tumor:

(show top 50) (show all 986)
# Title Authors PMID Year
1
Inhibition of cyclooxygenase-2 down-regulates aromatase activity and decreases proliferation of Leydig tumor cells. 61 54
19679653 2009
2
Leydig cell tumor and malignant lymphoma in a patient with nonclassical 21-hydroxylase deficiency. 61 54
19367056 2009
3
Detection of aromatase and estrogen receptors (ERalpha, ERbeta1, ERbeta2) in human Leydig cell tumor. 61 54
17656605 2007
4
Possible mechanism for testicular focal necrosis induced by hCG in rats. 54 61
17077584 2006
5
Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. 61 54
15753388 2005
6
Ribonucleic acid expression of the CLA-1 gene, a human homolog to mouse high density lipoprotein receptor SR-BI, in human adrenal tumors and cultured adrenal cells. 54 61
9253328 1997
7
Occurrence of FSH, inhibin and other hypothalamic-pituitary-intestinal hormones in normal fertility, subfertility, and tumors of human testes. 61 54
7749434 1995
8
Regulation of parathyroid hormone-related peptide production in vitro by the rat hypercalcemic Leydig cell tumor H-500. 61 54
8462465 1993
9
Extraadrenal expression of steroid 21-hydroxylase and 11 beta-hydroxylase by a benign testicular Leydig cell tumor. 54 61
1751389 1991
10
Leydig cell tumor estrogen secretion: suppression by a gonadotropin releasing hormone agonist. 54 61
1940064 1991
11
Measurement of circulating parathyroid hormone-related protein in rats with humoral hypercalcemia of malignancy using a two-site immunoradiometric assay. 61 54
2387260 1990
12
The structure of cDNA clones encoding the aromatase P-450 isolated from a rat Leydig cell tumor line demonstrates differential processing of aromatase mRNA in rat ovary and a neoplastic cell line. 54 61
2340950 1990
13
Detection of pure Leydig cell ovarian tumor not visible on imaging by selective venous blood sampling in a woman with secondary amenorrhea and hirsutism: A case report. 61
33665140 2021
14
Clinicopathological analysis of ovarian sertoli-leydig cell tumor with postmenopausal vaginal bleeding as the first symptom: A case report. 61
33787579 2021
15
Testicular leydig cell tumor revealed by hydrocele. 61
33318945 2021
16
Incidental Finding of Bilateral Ovarian Adrenal Rest Tumor in a Patient With Congenital Adrenal Hyperplasia: A Case Report and Brief Review. 61
33433255 2021
17
Ovarian Leydig cell tumor and postmenopausal hirsutism with signs of virilisation. 61
33731391 2021
18
The role of FOXL2, SOX9, and β-catenin expression and DICER1 mutation in differentiating sex cord tumor with annular tubules from other sex cord tumors of the ovary. 61
33566167 2021
19
[Leydig Cell Tumor in a Patient with Contralateral Cryptorchidism: A Rare Association]. 61
33637166 2021
20
Inhabitual presentation of Sertoli-Leydig cell tumor of the ovary with xeroderma pigmentosum: Case report with review of literature. 61
33383283 2021
21
Sertoli-Leydig Cell Tumors of the Ovary With Follicular Differentiation Often Resembling Juvenile Granulosa Cell Tumor: A Report of 38 Cases Including Comments on Sex Cord-Stromal Tumors of Mixed Forms (So-called Gynandroblastoma). 61
32815828 2021
22
Sertoli-Leydig cell tumor of the ovary: Radiologic-operative-histologic finding. 61
33218429 2020
23
Krukenberg Tumor of Ovary During Pregnancy: Learning From A Mistake. 61
33252404 2020
24
Cytoreduction with hyperthermic intra peritoneal and intra thoracic chemotherapy for metastatic Sertoli-Leydig cell tumor of the ovary. 61
32995452 2020
25
Mifepristone Treatment Promotes Testicular Leydig Cell Tumor Progression in Transgenic Mice. 61
33158280 2020
26
SEVERE HYPERANDROGENISM IN A PREMENOPAUSAL WOMAN WITH AN IMAGING-NEGATIVE LEYDIG CELL TUMOR. 61
33244487 2020
27
Glucagon-like peptide-1 receptor is expressed in human and rodent testis. 61
33460247 2020
28
Testis-Sparing Surgery for Non-Palpable Leydig Cell Tumors in Prepubertal Children. 61
33114483 2020
29
Poorly Differentiated Ovarian Sertoli-Leydig Cell Tumor in a 12-Month-Old Girl. 61
33343121 2020
30
SRY-Positive 46, XX Testicular Disorder of Sexual Development With Leydig Cell Tumor. 61
33131361 2020
31
Leydig cell tumor of a testis with azoospermia: A case report and literature review. 61
32899084 2020
32
The Masquerading, Masculinizing Tumor: A Case Report and Review of the Literature. 61
32991246 2020
33
Metachronous Sporadic Sextuple Primary Malignancies Including Bilateral Breast Cancers. 61
32908793 2020
34
An Excessive Testosterone Producing Testicular Leydig Cell Tumor as a Rare Cause of Secondary Acquired Erythrocytosis. 61
32289359 2020
35
Diagnosis of a small Leydig cell tumor by dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging. 61
32382371 2020
36
Ovarian Gynandroblastoma with a Juvenile Granulosa Cell Tumor Component in a Postmenopausal Woman. 61
32751726 2020
37
Sertoli-Leydig cell tumor in two siblings with DICER1 syndrome: A case report and literature review. 61
32629665 2020
38
Risk Factors and Treatment Outcomes of 1,375 Patients with Testicular Leydig Cell Tumors: Analysis of Published Case Series Data. 61
31845841 2020
39
[Ovarian Sertoli-Leydig cell tumors: DICER1 hotspot mutations and associated clinicopathological features]. 61
32392927 2020
40
Interstitial Leydig Cell Tumorigenesis-Leptin and Adiponectin Signaling in Relation to Aromatase Expression in the Human Testis. 61
32455738 2020
41
Postmenopausal mild hirsutism and hyperandrogenemia due to ovarian Sertoli-Leydig cell tumor: A case report. 61
32280807 2020
42
A testosterone-producing Leydig cell tumor metastasis during hormonal treatment of prostate cancer. 61
32565659 2020
43
An update on the central nervous system manifestations of DICER1 syndrome. 61
30953130 2020
44
Luteolin modulates gene expression related to steroidogenesis, apoptosis, and stress response in rat LC540 tumor Leydig cells. 61
31201582 2020
45
Precocious Pseudo-Puberty with Testicular Enlargement: Two Cases of Leydig Cell Tumor with Different Histopathological Results. 61
33262958 2020
46
Cáncer renal papilar tipo 2, asociado a piloleiomiomatosis y tumor testicular bilateral de células de Leydig. 61
33284259 2020
47
Management of Leydig cell tumors of the testis-a case report. 61
31754603 2020
48
Renal cell carcinoma in young FH mutation carriers: case series and review of the literature. 61
31792767 2020
49
DICER1 Syndrome and Cancer Predisposition: From a Rare Pediatric Tumor to Lifetime Risk. 61
33552988 2020
50
Ovarian tumors: a survey of selected advances of note during the life of this journal. 61
31654691 2020

Variations for Leydig Cell Tumor

Expression for Leydig Cell Tumor

Search GEO for disease gene expression data for Leydig Cell Tumor.

Pathways for Leydig Cell Tumor

GO Terms for Leydig Cell Tumor

Cellular components related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 organelle membrane GO:0031090 8.8 CYP21A2 CYP19A1 CYP17A1

Biological processes related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.78 PTHLH INSL3 INHA GNRH1
2 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.73 PTHLH LHCGR GNAS
3 female pregnancy GO:0007565 9.62 PTHLH PRL GNRH1 GNAS
4 adrenal gland development GO:0030325 9.57 NR5A1 NR0B1
5 regulation of neuronal synaptic plasticity GO:0048168 9.55 SYP STAR
6 estrogen biosynthetic process GO:0006703 9.54 STAR CYP19A1
7 sterol metabolic process GO:0016125 9.54 CYP21A2 CYP19A1 CYP11A1
8 C21-steroid hormone biosynthetic process GO:0006700 9.52 STAR CYP11A1
9 regulation of steroid biosynthetic process GO:0050810 9.51 STAR NR5A1
10 progesterone metabolic process GO:0042448 9.49 CYP17A1 AFP
11 cellular response to gonadotropin stimulus GO:0071371 9.46 STAR LHCGR
12 sex determination GO:0007530 9.43 NR5A1 NR0B1
13 male sex determination GO:0030238 9.43 NR5A1 NR0B1 GNRH1
14 cellular response to luteinizing hormone stimulus GO:0071373 9.4 STAR LHCGR
15 male gonad development GO:0008584 9.35 STAR NR5A1 NR0B1 LHCGR INHA
16 glucocorticoid biosynthetic process GO:0006704 9.33 CYP21A2 CYP17A1 CYP11A1
17 steroid biosynthetic process GO:0006694 9.02 STAR CYP21A2 CYP19A1 CYP17A1 CYP11A1

Molecular functions related to Leydig Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.62 CYP21A2 CYP19A1 CYP17A1 CYP11A1
2 iron ion binding GO:0005506 9.56 CYP21A2 CYP19A1 CYP17A1 CYP11A1
3 monooxygenase activity GO:0004497 9.46 CYP21A2 CYP19A1 CYP17A1 CYP11A1
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.26 CYP21A2 CYP19A1 CYP17A1 CYP11A1
5 hormone activity GO:0005179 9.02 PTHLH PRL INSL3 INHA GNRH1

Sources for Leydig Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....